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Abstract
Background: Coronary heart disease (CHD) is a leading cause of morbidity and mortality for breast cancer
survivors, yet the joint effect of adverse cardiovascular health (CVH) and cardiotoxic cancer treatments on posttreatment CHD and death has not been quantified.
Methods: We conducted statistical and machine learning approaches to evaluate 10-year risk of these outcomes
among 1934 women diagnosed with breast cancer during 2006 and 2007. Overall CVH scores were classified as
poor, intermediate, or ideal for 5 factors, smoking, body mass index, blood pressure, glucose/hemoglobin A1c, and
cholesterol from clinical data within 5 years prior to the breast cancer diagnosis. The receipt of potentially
cardiotoxic breast cancer treatments was indicated if the patient received anthracyclines or hormone therapies. We
modeled the outcomes of post-cancer diagnosis CHD and death, respectively.
Results: Results of these approaches indicated that the joint effect of poor CVH and receipt of cardiotoxic
treatments on CHD (75.9%) and death (39.5%) was significantly higher than their independent effects [poor CVH
(55.9%) and cardiotoxic treatments (43.6%) for CHD, and poor CVH (29.4%) and cardiotoxic treatments (35.8%) for
death].
Conclusions: Better CVH appears to be protective against the development of CHD even among women who had
received potentially cardiotoxic treatments. This study determined the extent to which attainment of ideal CVH is
important not only for CHD and mortality outcomes among women diagnosed with breast cancer.
Keywords: Cancer informatics, Machine learning, Precision medicine, Coronary heart disease, Death, Breast Cancer,
Cancer treatments, Interactions

Background
Coronary heart disease (CHD) is the leading cause of
death among all women [1], including breast cancer survivors [2–4]. Increased utilization of screening and treatment has led to more than 3.5 million female breast
cancer survivors in the United States today [5, 6]. The
majority of these women are more likely to die of CHD
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than cancer [2–4, 7, 8]. CHD is a serious issue, because
important risk factors, such as physical inactivity, unhealthy diet, obesity, and smoking, are common to the
etiology of both CHD and breast cancer [1, 9–11].
Cardiovascular health (CVH), as defined recently by
the American Heart Association (AHA), has important
implications for the prevention of both CHD and cancer
[12, 13]. CVH factors are believed to operate in common
pathways to chronic disease. For example, adverse CVH
factors may be pro-inflammatory and also may be carcinogenic. To date, many community-based studies have
used the CVH metric to characterize the prevalence of
ideal CVH in population-based samples [14–19]. Our
previous work in the Women’s Health Initiative (WHI)
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found that a poorer ideal CVH score, comprising the
aforementioned factors plus blood pressure, cholesterol,
and glucose, was associated with a higher incidence of
cardiovascular disease, cancer, and breast cancer specifically [20].
Our evaluation of California cancer registry data
highlighted the possible role of shared risk factors in the
development of both cancer and CHD, reporting that
cancer survivors tend to have multiple CHD risk factors,
and that survivorship care often does not address these
risk factors [21, 22]. Favorable levels of risk factors common to both CHD and cancer are associated with improved CHD and cancer survival [23]. Yet, in addition to
the problem of shared risk factors, therapies used to
treat breast cancer are linked with cardiovascular injury,
thus increasing CHD susceptibility via the “multiple-hit”
hypothesis [24–33]. Breast cancer therapies that are potentially cardiotoxic include chemotherapies, radiotherapy, hormonal treatments, and monoclonal antibodies
[24].
To our knowledge, existing studies have not yet
assessed the joint effect (interaction) of predisposing cardiovascular risk factors and cancer treatments among
breast cancer survivors. Subpopulations, such as breast
cancer survivors in poor CVH prior to their cancer diagnosis, may be particularly susceptible to the late effects
of chemotherapy, radiation, and other cancer treatments.
Thus, this analysis will build on our previous work in
the WHI which assessed the relationship between CVH
and incident CHD and cancer [20].
A better understanding of synergistic associations between poor CVH and breast cancer treatments on CHD
risk after breast cancer has the potential to guide CHD
and cancer treatment, as well as post-treatment cancerrelated follow-up care is warranted. Screening and treatment of poor CVH at the time of cancer diagnosis and
treatment planning may improve morbidity and mortality from CHD among breast cancer survivors [4, 21, 34–
36]. Existing literature indicates that left-sided radiation,
in certain doses, has a synergistic effect with pre-existing
cardiac risk factors on the risk of ischemic heart disease
[17]. Our goal was to add to this literature by investigating the receipt of radiation alongside other types of cancer therapies on risk of CHD and mortality using novel
statistical techniques [37].
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investigate the association between CVH, potentiallycardiotoxic cancer treatments, age, race, and the 10-year
risk of post-treatment CHD [38] and death, respectively.
We defined CHD according to 217 unique ICD 9/10
diagnosis codes and 14 unique procedure codes, and
date of death was ascertained from EHR data which
were updated regularly with data from the National
Death Index.
We utilized measures of CVH as follows: smoking status, body mass index (BMI), blood pressure, glucose/
hemoglobin A1c, and cholesterol [20], which were introduced by the AHA and shown in detail in Table 1. The
most recent CVH data were ascertained within the 5
years prior to the diagnosis of breast cancer. We used
these baseline data to assign a pre-treatment CVH score
to each woman with a breast cancer diagnosis. A value
of “ideal” corresponded with 2 points on that submetric;
a value of “intermediate” with 1 point; and a value of
“poor” with 0 points.
For smoking status, for which data were complete, we
classified current smoking as 0 points, and not current
smoking as 1 point, as there were no data available to indicate if they had never smoked or had quit for more
than 1 year (representing the “ideal” category). However,
not all CVH data were completed for all women; therefore, we imputed a value of 2 points for all missing submetric values. We tested the robustness of this strategy
by imputing a value of 1 or 0, respectively, for missing
values. For all analyses, overall CVH was calculated by a
sum of all points, divided by the total possible points
[10], and multiplied by 100, and was defined as: 0- < 30%
for poor; 30- < 80% for intermediate; and 80–100% as
ideal.
Of interest for these analyses were the following treatments, due to their potential adverse effects on the myocardium: chemotherapy, left-sided radiation, hormonerelated or anti-estrogen pills, and Herceptin. We categorized the breast cancer treatments as eight categories according to what medicines were ordered: anthracyclines,
hormone therapy, aromatase inhibitors, monoclonal
antibodies, antimicrotubule agents, alkylating agents, antimetabolites, and other (e.g., Bortezomib). In our
current analysis, we included the receipt (yes/no) of each
type of treatment.
Statistical analysis

Methods
Data source and study design

In this study, electronic health record (EHR) data was
obtained from a large midwestern medical center. The
patients (n = 1934) were all initially diagnosed with
breast cancer during 2006 or 2007 and did not have preexisting CHD. We included follow-up data for 10 years
following the initial diagnosis. Our goal was to

We classified age into three groups: 20–40, 41–60, and
61–100 years. The age is the age at the breast cancer
diagnosis. Race/ethnicity was defined as: black, nonblack, and unknown. After we quantified and categorized
the features of CVH, cancer treatments, age, and race,
we applied both traditional statistical methods and machine learning algorithms [i.e., support vector machines
(SVM) [39], decision tree [40], and logistic regression
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Table 1 Measures of CVH in the EHR (Adapted from Lloyd-Jones, 2011) [38]
Poor Health

Intermediate Health

Ideal Health

Smoking status

Yes

Former ≤12 months

Never or quit > 12
months

Body mass index

≥ 30 kg/m2

25–29.9 kg/m2

< 25 kg/m2

Total cholesterol

≥ 240 mg/dL

200–239 mg/dL or treated to goal

< 200 mg/dL

Blood pressure

Systolic ≥140 mmHg or Diastolic ≥90
mmHg

Systolic 120–139 mmHg or Diastolic 80–89 mmHg or
treated to goal

Systolic < 120 mmHg
Diastolic < 80 mmHg

Fasting plasma
glucose

≥ 126 mg/dL

100–125 mg/dL or treated to goal

< 100 mg/dL

Health Behaviors

Health Factors

[41]] to investigate the associations between age, race,
CVH, cancer treatments, the interaction between CVH,
cancer treatments, and CHD and all-cause mortality, respectively. We also conducted the Welch’s t-test and
produced boxplots to evaluate the differences between
independent and joint effects of CVH and cancer treatments. In the machine learning models, we used CVH,
treatment and the interaction of CVH and treatment as
features, and applied linear SVM, decision tree, and logistic regression models, respectively, to predict if a
woman had incident CHD or death during 10 years of
follow-up. For the death prediction, we randomly selected a similar number of patients who had died (n =
468) to compare to a sample of patients who had not
died (n = 374) due to the imbalance of our data according to mortality. We used all patient observations in the
CHD risk prediction models. We tested the 5 CVH submetrics and 8 treatment categories as input features for
the classification models. The dataset was randomly split
into training (80%) and test (20%) data sets, on which
the models were trained and then applied. Criteria of accuracy and area under the receiver operator curve
(AUC) were calculated to evaluate the performance of
the models. Analyses were conducted by using the libraries of Scikit-learn, Scipy, Matplotlib with Python,
version 3.6.5 (2018).

Results
The average age of the population was 58.5 years, and
the majority of women (73%) were non-black (Table 2).
Approximately 20% of women were currently taking a
cholesterol medication, and few women (3%) were
current smokers (Table 2). There were 341 patients with
receipt of any class of cardiotoxic cancer treatments.
Among these 341 patients, 46% women received aromatase inhibitors and 26% women received hormone therapy. During the 10-year follow-up period, one-third of
the population developed CHD and 19% died.
Figure 1 shows the counts of women with each outcome of interest and the proportion of women

represented in that strata. Women with a lower occurrence of CHD were younger (20–40 years), and the
prevalence of CHD steadily increased across older age
groups (Fig. 1a). Black women experienced a higher occurrence (48%) of CHD compared to the other race
groups (31%) (Fig. 1b). Rates of CHD were lower among
women with an ideal CVH score (24%) as compared to
those with CVH at non-ideal levels (61.9%) (Fig. 1c). Receipt of potentially cardiotoxic breast cancer treatments
was associated with an increased occurrence of posttreatment CHD. Rates of incident CHD were higher
among women who received any cancer treatment
(58.9%) compared to the women who did not receive
any cancer treatments (29.1%) (Fig. 1d). We observed
similar trends for the outcome of mortality (Fig. 1e-h).
Particularly, Fig. 1f shows 29% of the black women died
compared to 15.9% for the non-black race; Fig. 1h shows
that higher percentage of patients died in the recipient
of treatment group. Women who died during the 10year follow-up tended to be older, of black race, who received cancer treatments, and who had non-ideal CVH.
In Fig. 2, we show the independent and joint effects of
receipt of cardiotoxic breast cancer treatments and
poorer CVH. Women in poor (non-ideal) CVH who
were also exposed to cardiotoxic treatments had a synergistically higher occurrence of post-treatment CHD
(75.9%) compared to women not exposed to cardiotoxic
treatments who were in good CVH (20.8%) (Fig. 2a).
Women in poor CVH who were not exposed to cardiotoxic treatments, as well as women in good CVH who
were exposed to cardiotoxic treatments, had an elevated
occurrence of post-treatment CHD (55.9 and 43.6% respectively), but did not experience a rate as high as those
who were doubly-exposed. Similar trends were observed
for the outcome of mortality (Fig. 2b). In addition, the
independent effect of treatment is bigger on CHD
(43.6%) than on death (35.8%).
The boxplots in Fig. 2c also indicate the significant difference between CHD rates among women who were
doubly-exposed and the women who were independently
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Table 2 Characteristics [mean (SD) or n (%)] of the study population (n = 1934)
Total (n = 1934)

CHD(n = 664)

Death (n = 374)

58.5 (12.9)

62.9 (13.1)

61.4 (13.9)

Age (years)
Mean (SD)
20–40

135 (7.0)

23 (3.5)

23 (6.1)

> 40–60

975 (50.4)

260 (39.2)

159 (42.5)

> 60–100

824 (42.6)

381 (57.4)

192 (51.3)

Black

435 (22.5)

209 (31.5)

126 (33.7)

Non-black

1419 (73.4)

433 (65.2)

226 (60.4)

Race

80 (4.1)

22 (3.3)

22 (5.9)

BMI (kg/m2)

Unknown

21.9 (13.6)

29.3 (8.3)

28.1 (10.1)

Systolic blood pressure (SBP, mmHg)

125.4 (20.7)

128.4 (22.0)

126.0 (20.7)

Diastolic blood pressure (DBP, mmHg)

69.8 (11.2)

69.8 (11.6)

69.4 (11.4)

Fasting glucose (mg/dL)

109.3 (33.3)

129.9 (53.6)

127.6 (58.3)

Hemoglobin A1c (%)

6.94 (1.9)

7.05 (1.8)

7.45 (2.3)

Total cholesterol (mg/dL)

186.6 (50.3)

181.6 (46.6)

178.9 (61.0)

Current smoking

66 (3.4)

51 (7.7)

18 (4.8)

Taking antihypercholesterolemia medication

367 (19.0)

267 (40.2)

88 (23.5)

Taking antihypertensive medication

461 (23.8)

386 (58.1)

215 (57.5)

Taking diabetic medications

346 (17.9)

238 (35.8)

138 (36.9)

Classes of potentially cardiotoxic cancer treatmentsa
Total patients (%) receiving treatments

341 (17.6)

201 (30.3)

128 (34.2)

Anthracyclines

6 (1.8)

4 (2.0)

3 (2.3)

Hormone therapy

87 (25.5)

51 (25.4)

28 (21.9)

Aromatase inhibitors

158 (46.3)

97 (48.3)

44 (34.3)

Monoclonal antibodies

7 (2.1)

3 (1.5)

2 (1.6)

Antimicrotubule agents

15 (4.4)

9 (4.5)

9 (7.0)

Alkylating agents

21 (6.2)

12 (6.0)

12 (9.4)

Antimetabolites

37 (10.9)

20 (10.0)

27 (21.1)

Other

10 (2.9)

5 (2.5)

3 (2.3)

a

The percentages for each class of treatments used 341, 201 and 128 as the denominator

exposed to poor CVH and cancer treatments (p < 0.0001
for poor CVH vs. joint exposure, p < 0.0001 for cancer
treatments vs. joint exposure). We observed similar results for the outcome of mortality shown in Fig. 2d (p <
0.0001 for poor CVH vs. joint exposure, p < 0.007 for
cancer treatments vs. joint exposure).
We obtained similar results using machine learning
models. Table 3/4 (in the supplementary material) lists
the performance results for death/CHD prediction by
the three models. The accuracy for predicting death by
SVM was 69% for models containing CVH (68% by decision tree, 69% by logistic regression), 63% for models
containing cancer treatment (69% by decision tree, 66%
by logistic regression) and 70% for models containing
both CVH and treatment (72% by decision tree, 72% by
logistic regression). The metrics of precision, recall and

f1-score had a similar trend for the prediction. The prediction performance results held the same trends for the
CHD prediction (Table 4).
The first column in Fig. 3 shows the AUC plots for
CHD prediction while the second column shows the
prediction characteristics for the outcome of death by
SVM, decision tree, and logistic regression classifiers
under three different conditions of features: CVH,
cancer treatments, and combined CVH and cancer
treatments. The average AUC of the three machine
learning models was 0.65 for CVH, 0.60 for cancer
treatment, and 0.73 for both CVH and cancer treatments. We obtained similar results for the mortality
analyses. We also performed 10-fold cross validation
for each model and the results were similar (data not
shown).
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Fig. 1 Associations between age, race, CVH, treatment and CHD or death. a-d show associations between age (a), race (b), CVH (c), treatment (d)
and CHD. e-h show associations between age (e), race (f), CVH (g), treatment (h) and death. In c and g, CVH is ideal if CVH = 2.0, and
intermediate if CVH = 1.0

The results from Table 3 and Fig. 3 indicate that all
three models achieved higher accuracy with the inclusion of joint effects as compared to only individual effects. Specifically, models which include both CVH and
receipt of treatment data provide additional information
and improve the prediction of CHD and death. Patients

with poor overall CVH who received cancer treatments
had the highest risk of CHD and death.

Discussion
In this study, we utilized data from the EHR to identify
women who were diagnosed with breast cancer in order
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Fig. 2 Associations between joint effects/interactions and CHD or death. a and b show the contribution of CVH and treatments on CHD (a) and
death (b). c and d are box plots of the individual and joint (interaction) effects of CVH and treatments on CHD (c) and death (d). In a and b, CVH
is ideal if CVH = 2.0, and intermediate if CVH = 1.0

to examine the independent and joint effects of CVH
and cancer treatments on 10-year risk of post-treatment
CHD or death. Our results indicated women with ideal
CVH scores, and those who did not receive potentially
cardiotoxic cancer treatments had the lowest risk of
post-treatment CHD or death, while the joint effects of
poor CVH and exposure to cancer treatments significantly increased the risk of post-treatment CHD or
death. Additional factors that were associated with a
higher prevalence of CHD and death included older age
and black race.
Our results were consistent with previous conclusions
that minority and older adults were more likely to have
poorer CVH and ideal CVH was inversely associated
with cancers and cardiovascular disease [20]. Consistent
with biologic plausibility, our results indicated a higher
risk of post-treatment CHD among those who received
breast cancer treatments such as ionizing radiation to
the heart [27].
The innovation in this study was to investigate the
joint effects of CVH and potentially cardiotoxic breast
cancer treatments by both statistical methods and multiple machine learning approaches. The results from all

these methods were consistent, indicating the robustness
of our methods and results.
Our next step is to investigate some questions such as
which individual treatments (e.g. anthracyclines, hormone therapy) and individual CVH submetrics (e.g.
BMI, blood pressure) are the most important variables
for predicting CHD and death, but these questions are
beyond the scope of this paper. We also plan to replicate
these analyses in distinct cancer types.
Another next step is to involve deploying and evaluating
clinical decision support in the cancer survivorship setting
for managing cardiovascular late effects among cancer
survivors. Our clinical decision support system (CDSS)
presents CVH and cancer treatment data separately in the
EHR-embedded data visualization. Our goal is to 1 day integrate a validated cardiovascular risk algorithm into our
existing CDSS to better target cardiovascular disease prevention and management efforts in cancer survivorship.

Limitations
We encountered many limitations in using EHR data for
these analyses. First, there were many missing data for
CVH, likely because these women were not being seen
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Fig. 3 The first column (a-c) represent CHD prediction, and the second column (d-f) show results of mortality prediction. a and d show the AUC
in ROC by SVM models, b and e show the AUC in ROC by decision tree models, and c and f show the AUC in ROC by logistic regression models.
The three curves in each plot represent the individual and joint effects of CVH and potentially-cardiotoxic treatments

for preventive care but rather for cancer care and treatment. Second, we acknowledge that we may be missing
CHD and mortality outcome data for women who obtained cancer care and treatment at our medical center
but after which returned home and sought care outside
of our medical center. Third, we used CVH measurements up to 5 years prior to the cancer diagnosis, of
which the time frame varied for each woman. Fourth,
physical activity and diet data are not commonly recorded in the EHR as structured, actionable data elements. If physical activity and diet data do exist in the
EHR, they are usually recorded as clinical notes using
free text. Importantly, these data are not easily translated
into the American Heart Association’s metric definitions
and thus are not actionable at the point-of-care or easily

incorporated into risk scoring algorithms. Similarly, data
on diagnosis and treatment, have not always been stored
as structured data elements in the EHR. Conducting this
analysis required mining data from legacy EHR systems
and for pragmatic reasons we accessed only structured
data elements for this analysis, which resulted in incomplete data ascertainment. Finally, we are missing data on
radiotherapy. We will explore the missing radiotherapy
data from multiple data sources as our future work.

Conclusions
An ideal CVH score predicted a lower risk of posttreatment CHD or death. Receipt of cardiotoxic breast
cancer treatments was associated with increased posttreatment CHD or death, and there was a synergistic
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effect of CVH such that better CVH seemed to be protective against the development of CHD even among
women who had received potentially cardiotoxic treatments. This study determined the extent to which ideal
CVH is important to attain and maintain for more favorable outcomes following a breast cancer diagnosis.
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